In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.
Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.
Despite improvements in heart health, cardiovascular deaths linked to substance use have risen by 4 percent annually from 1999–2019, a recent study shows.
Study finds that high levels of HDL may not be protective against heart disease, and low levels were linked to higher heart attack risk in just white participants but not Black participants.